A new era for translational atopic dermatitis research and management

Kabashima, Kenji; Biedermann, Tilo

doi:10.1111/exd.13546

Cited by 3 publications

(5 citation statements)

References 59 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assessing mental health Primary hyperhidrosis, emotional change, stress [ 43,[76][77][78] Skin hydration Cosmetic Testing the efficacy of cosmetics Topical products, oral supplementation [49,50,[79][80][81] Disease Assisting disease diagnostics/care/treatment Atopic dermatitis, psoriasis [21,82,83] Psychological Assessing mental health Emotional change, stress [ 84,85] Easing the exacerbation of skin condition Atopic dermatitis, wound healing [ 86,87] Other Allergic tests, observation of the newborn, skin burns [88] wearable SLMDs with a larger measurement range to monitor sweat loss during sports.…”

Section: Psychologicalmentioning

confidence: 99%

“…[ 101 , 102 , 103 ] The reason is not only that its water delivery, whose volume is higher than that of insensible sweat, can moisturize the skin more effectively, but it also contains natural moisturizing compounds, such as lactate, urea, sodium, and potassium. [ 104 ] Monitoring the ability to secrete sensible sweat would be valuable when diagnosing, curing, and treating allergic skin diseases such as atopic dermatitis, [ 83 ] and when investigating how such diseases progress. [ 103 ]…”

Section: Significance Of Measuring Sweat Lossmentioning

confidence: 99%

See 1 more Smart Citation

Wearable Sweat Loss Measuring Devices: From the Role of Sweat Loss to Advanced Mechanisms and Designs

et al. 2021

View full text Add to dashboard Cite

Wearable sweat sensors have received significant research interest and have become popular as sweat contains considerable health information about physiological and psychological states. However, measured biomarker concentrations vary with sweat rates, which has a significant effect on the accuracy and reliability of sweat biosensors. Wearable sweat loss measuring devices (SLMDs) have recently been proposed to overcome the limitations of biomarker tracking and reduce inter-and intraindividual variability. In addition, they offer substantial potential for monitoring human body homeostasis, because sweat loss plays an indispensable role in thermoregulation and skin hydration. Previous studies have not carried out a comprehensive and systematic review of the principles, importance, and development of wearable SLMDs. This paper reviews wearable SLMDs with a new health perspective from the role of sweat loss to advanced mechanisms and designs. Two types of sweat and their measurement significance for practical applications are highlighted. Then, a comprehensive review of advances in different wearable SLMDs based on hygrometers, absorbent materials, and microfluidics is presented by describing their respective device architectures, present situations, and future directions. Finally, concluding remarks on opportunities for future application fields and challenges for future sweat sensing are presented.

show abstract

Section: Psychologicalmentioning

confidence: 99%

Section: Significance Of Measuring Sweat Lossmentioning

confidence: 99%

Wearable Sweat Loss Measuring Devices: From the Role of Sweat Loss to Advanced Mechanisms and Designs

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[66] The positive results of these studies substantiate that inhibition of the type 2 cytokines IL-4 and IL-13 through the blockade of the IL4r is an effective way of treating patients with AD but have also stimulated interest in applying this therapeutic approach to other diseases in which the IL-4 and IL-13 axis is known to be elevated, including ongoing clinical trials for asthma therapy. In 2017, dupilumab was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as the first biological therapy for AD.…”

Section: Atopic Dermatitis and The Role Of Type 2 Immunologymentioning

confidence: 89%

“…In 2017, dupilumab was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as the first biological therapy for AD. [66] The positive results of these studies substantiate that inhibition of the type 2 cytokines IL-4 and IL-13 through the blockade of the IL4r is an effective way of treating patients with AD but have also stimulated interest in applying this therapeutic approach to other diseases in which the IL-4 and IL-13 axis is known to be elevated, including ongoing clinical trials for asthma therapy. [67] As outlined in this review the initial targeting idea of blocking the alpha chain subunit of the IL-4 and IL-13 receptor was supported by bioinformatics.…”

Section: Atopic Dermatitis and The Role Of Type 2 Immunologymentioning

confidence: 96%

Translational drug discovery and development with the use of tissue‐relevant biomarkers: Towards more physiological relevance and better prediction of clinical efficacy

Florian

Flechsenhar

Bartnik

et al. 2019

Experimental Dermatology

View full text Add to dashboard Cite

Due to the clinical development of drugs such as secukinumab, ustekinumab and dupilumab, major changes have been achieved in the treatment of patients diagnosed with psoriasis and atopic dermatitis. In academia and the pharmaceutical industry, research is increasingly moving towards the development of bispecific antibodies and multi‐specific nanobodies, as there is a compelling need for new treatment modalities for patients suffering from autoimmune or malignant disease. The purpose of this review is to discuss aspects of translational drug development with a particular emphasis on indications such as psoriasis and atopic dermatitis. The identification of biomarkers, the assessment of target organ pharmacokinetic and pharmacodynamics interactions and a wide range of in vitro, ex vivo and in vivo models should contribute to an appropriate prediction of a biological effect in the clinical setting. As human biology may not be perfectly reflected by approaches such as skin equivalents or animal models, novel approaches such as the use of human skin and dermal microperfusion assays in healthy volunteers and patients appear both reasonable and mandatory. These models may indeed generate highly translationally relevant data that have the potential to reduce the failure rate of drugs currently undergoing clinical development.

show abstract

“…AD is caused by a combination of genetic and environmental factors; therefore, skin inflammation is determined by both allergic and non-allergic mechanisms. In addition, severity of AD could be determined by frequency and type of mutations in genes involved in skin barrier function (ie, FLG – FLG2-SPINK5) 5…”

Section: Introductionmentioning

confidence: 99%

Comorbidity between progressive familial intrahepatic cholestasis and atopic dermatitis in a 19-month-old child

et al. 2019

View full text Add to dashboard Cite

Atopic dermatitis (AD) is the most common chronic skin disease in children, with an increasing prevalence in the past three decades. Adequate treatment is prescribed for individual patient based on symptoms and disease severity. However, further underlying diagnosis should be researched when therapeutic strategies for symptoms fail and skin lesions and pruritus persist. We reported herein the case of a 19-month-old infant with a history of AD unresponsive to treatment due to the type 2 progressive familial intrahepatic cholestasis (PFIC). A new homozygous mutation of the ABCB11 gene was found. The severe pruritus, the early onset jaundice, poor growth and raised transaminase levels with normal gamma glutamyl transpeptidase have led to the suspicion of PFIC. The presence of severe AD and intrahepatic chronic cholestasis, both pruritus associated, could delay a proper diagnosis. To our knowledge, for the first time, a case of comorbidity between type 2 PFIC and AD-like disease had been described.

show abstract

A new era for translational atopic dermatitis research and management

Cited by 3 publications

References 59 publications

Wearable Sweat Loss Measuring Devices: From the Role of Sweat Loss to Advanced Mechanisms and Designs

Wearable Sweat Loss Measuring Devices: From the Role of Sweat Loss to Advanced Mechanisms and Designs

Translational drug discovery and development with the use of tissue‐relevant biomarkers: Towards more physiological relevance and better prediction of clinical efficacy

Comorbidity between progressive familial intrahepatic cholestasis and atopic dermatitis in a 19-month-old child

Contact Info

Product

Resources

About